935 related articles for article (PubMed ID: 31755958)
21. Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies.
Tagliafierro L; Glenn OC; Zamora ME; Beach TG; Woltjer RL; Lutz MW; Chiba-Falek O
Alzheimers Dement; 2017 Nov; 13(11):1237-1250. PubMed ID: 28431219
[TBL] [Abstract][Full Text] [Related]
22. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses.
Creese B; Bell E; Johar I; Francis P; Ballard C; Aarsland D
Am J Med Genet B Neuropsychiatr Genet; 2018 Mar; 177(2):232-241. PubMed ID: 28548708
[TBL] [Abstract][Full Text] [Related]
23. Genetic mechanism vs genetic subtypes: The example of GBA.
Senkevich K; Rudakou U; Gan-Or Z
Handb Clin Neurol; 2023; 193():155-170. PubMed ID: 36803808
[TBL] [Abstract][Full Text] [Related]
24. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
[TBL] [Abstract][Full Text] [Related]
25. GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson's disease.
Senkevich K; Zorca CE; Dworkind A; Rudakou U; Somerville E; Yu E; Ermolaev A; Nikanorova D; Ahmad J; Ruskey JA; Asayesh F; Spiegelman D; Fahn S; Waters C; Monchi O; Dauvilliers Y; Dupré N; Greenbaum L; Hassin-Baer S; Grenn FP; Chiang MSR; Sardi SP; Vanderperre B; Blauwendraat C; Trempe JF; Fon EA; Durcan TM; Alcalay RN; Gan-Or Z
Brain; 2023 May; 146(5):1859-1872. PubMed ID: 36370000
[TBL] [Abstract][Full Text] [Related]
26. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
Winder-Rhodes SE; Evans JR; Ban M; Mason SL; Williams-Gray CH; Foltynie T; Duran R; Mencacci NE; Sawcer SJ; Barker RA
Brain; 2013 Feb; 136(Pt 2):392-9. PubMed ID: 23413260
[TBL] [Abstract][Full Text] [Related]
27. A common polymorphism in
Stoker TB; Camacho M; Winder-Rhodes S; Liu G; Scherzer CR; Foltynie T; Barker RA; Williams-Gray CH
J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):673-674. PubMed ID: 32241921
[No Abstract] [Full Text] [Related]
28. Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S
Grigor'eva EV; Kopytova AE; Yarkova ES; Pavlova SV; Sorogina DA; Malakhova AA; Malankhanova TB; Baydakova GV; Zakharova EY; Medvedev SP; Pchelina SN; Zakian SM
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901867
[No Abstract] [Full Text] [Related]
29. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Barkhuizen M; Anderson DG; Grobler AF
Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
[TBL] [Abstract][Full Text] [Related]
30. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.
Velayati A; Yu WH; Sidransky E
Curr Neurol Neurosci Rep; 2010 May; 10(3):190-8. PubMed ID: 20425034
[TBL] [Abstract][Full Text] [Related]
31. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
32. High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews.
Shiner T; Mirelman A; Gana Weisz M; Bar-Shira A; Ash E; Cialic R; Nevler N; Gurevich T; Bregman N; Orr-Urtreger A; Giladi N
JAMA Neurol; 2016 Dec; 73(12):1448-1453. PubMed ID: 27723861
[TBL] [Abstract][Full Text] [Related]
33. Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.
Ran C; Brodin L; Forsgren L; Westerlund M; Ramezani M; Gellhaar S; Xiang F; Fardell C; Nissbrandt H; Söderkvist P; Puschmann A; Ygland E; Olson L; Willows T; Johansson A; Sydow O; Wirdefeldt K; Galter D; Svenningsson P; Belin AC
Neurobiol Aging; 2016 Sep; 45():212.e5-212.e11. PubMed ID: 27255555
[TBL] [Abstract][Full Text] [Related]
34. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.
Pchelina S; Emelyanov A; Baydakova G; Andoskin P; Senkevich K; Nikolaev M; Miliukhina I; Yakimovskii A; Timofeeva A; Fedotova E; Abramycheva N; Usenko T; Kulabukhova D; Lavrinova A; Kopytova A; Garaeva L; Nuzhnyi E; Illarioshkin S; Zakharova E
Neurosci Lett; 2017 Jan; 636():70-76. PubMed ID: 27780739
[TBL] [Abstract][Full Text] [Related]
35. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
36. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
37. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson's disease-associated GBA gene.
Toffoli M; Chen X; Sedlazeck FJ; Lee CY; Mullin S; Higgins A; Koletsi S; Garcia-Segura ME; Sammler E; Scholz SW; Schapira AHV; Eberle MA; Proukakis C
Commun Biol; 2022 Jul; 5(1):670. PubMed ID: 35794204
[TBL] [Abstract][Full Text] [Related]
39. Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression.
Davis AA; Andruska KM; Benitez BA; Racette BA; Perlmutter JS; Cruchaga C
Neurobiol Aging; 2016 Jan; 37():209.e1-209.e7. PubMed ID: 26601739
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
